A Double-blind, Multi-center, Multi-regional, Randomized Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed with COVID-19
Not Applicable
Terminated
- Conditions
- Codes for special purposes
- Registration Number
- KCT0006614
- Lead Sponsor
- Chong Kun Dang
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Terminated
- Sex
- All
- Target Recruitment
- 586
Inclusion Criteria
1) Patients aged = 18 years
2) Patients diagnosed with COVID-19 infection and pneumonia
3) Patients who have voluntarily decided to participate in the study and signed the informed consent form
Exclusion Criteria
1) Patients with history of hypersensitivity to the study drug
2) Female patients, either who are or may be pregnant or who are breastfeeding, or female patients of child-bearing potential who are unable to use adequate contraception during the study
3) Patients who are deemed to ineligible to participate in the study for other reasons by the investigator
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to recovery
- Secondary Outcome Measures
Name Time Method Time to clinical improvement